Gastroenterology
Xu X, Chehade M, Kwiatek J, Maslova E, Kielar D, Stirnadel-Farrant H, Meyers J, Aceves S. Demographics and clinical characteristics of patients with eosinophilic esophagitis: a US-based insurance claims data analysis. Poster presented at the 2022 ACAAI Annual Scientific Meeting; November 10, 2022. Louisville, KY.
INTRODUCTION: Real-world data on demographics and clinical characteristics of patients with eosinophilic esophagitis (EoE) are limited. We described patient characteristics, clinical symptoms, and comorbidities in US patients with newly-diagnosed EoE.
Xu X, Kwiatek J, Chehade M, Aceves S, Maslova E, Kielar D, Stirnadel-Farrant H, Meyers J, Candrilli S, Katial R. Characteristics of and healthcare cost drivers among U.S. patients with eosinophilic esophagitis with high versus non-high all-cause costs: an analysis of insurance claims data. Poster presented at the 2022 American College of Gastroenterology (ACG) Annual Scientific Meeting; October 24, 2022. Charlotte, NC.
Danese S, Kamble P, Yang J, Le Moine JG, Khan S, Hawe E, Agboton C, Wang S, Irving PM. Vedolizumab rates of mucosal healing in Crohn's disease: a systematic literature review and meta-analysis of real-world data. Presented at the 2021 Digestive Disease Week Virtual Conference; May 23, 2021.
Danese S, Kamble P, Yang J, Le Moine JG, Khan S, Hawe E, Agboton C, Wang S, Irving PM. Systematic literature review and meta-analysis: real-world mucosal healing in Vedolizumab-treated patients with Crohn's disease. GastroHep. 2022 Feb 16. doi: 10.1155/2022/6975416
BACKGROUND: Vedolizumab is a gut-selective monoclonal anti-α4β7-integrin antibody approved for the treatment of adults with moderately to severely active Crohn’s disease (CD).
Osborne R, Nelson L, Fehnel S, Williams N, Bender RH, Ziemiecki R, Gymnopoulou E, De Paepe E, Norcross L, Heijnen E, Ispas G, Cheret A, Comeaux C, Callendret B, Vandendijck Y, Chan E, Scott J. Measurement of symptoms in respiratory syncytial virus–infected adults: meaningful within-patient change thresholds for the respiratory infection intensity and impact questionnaire (RiiQ). Poster presented at the 8th ESWI Influenza Conference Scientific and SPI Virtual Programme; December 4, 2021.
Abstract not available at this time.
Gold BD, Goodwin B, Davis K, Sweeney C, Reynolds M, Jiang J, Fan T, Boules M, Desai NK, Katzka DA. Treatment burden and associated costs in adolescents and adults with eosinophilic esophagitis in the USA. Poster presented at the AMCP Nexus 2021; October 19, 2021. [abstract] J Manag Care Pharm. 2021 Oct; 27(10-a):S82.
BACKGROUND: Eosinophilic esophagitis (EoE) is a chronic disease for which there is currently no US Food and Drug Administration-approved pharmacologic therapy. Patients thus rely on off-label medication and dietary modification.
Gold BD, Goodwin B, Davis K, Sweeney C, Garbinsky D, Jiang J, Fan T, Boules M, Desai NK, Katzka DA. Perceptions of disease stigma in adolescents and adults with eosinophilic esophagitis in the US. Poster presented at the 2021 Annual Scientific Meeting & Postgraduate Course (ACG); October 24, 2021. Las Vegas, NV. [abstract] Am J Gastroenterol. 2021 Oct; 116:S176-7. doi: 10.14309/01.ajg.0000774072.42679.92
Gold BD, Goodwin B, Davis K, Sweeney C, Reynolds M, Jiang J, Fan T, Boules M, Desai NK, Katzka DA. Health-related quality of life in adolescents and adults with eosinophilic esophagitis in a real world setting in the US. Poster presented at the 2021 Annual Scientific Meeting & Postgraduate Course (ACG); October 24, 2021. Las Vegas, NV. [abstract] Am J Gastroenterol. 2021 Oct; 116:S176. doi: 10.14309/01.ajg.0000774068.59482.1e
INTRODUCTION: The disease burden of eosinophilic esophagitis (EoE) can be highly variable, with some patients reporting persistent symptoms that may represent significant daily physical and emotional burdens. The impact of EoE on health-related quality of life (HRQoL) has not been well documented.